Search

everythinglearnresearchcommunity

for

Search:↓

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Low-dose dutasteride (0.1 mg) is effective for hair growth, potentially more so than finasteride, with fewer side effects. East Asians may respond well to these treatments due to hair characteristics.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

Topical dutasteride may have limited absorption due to its higher molecular mass compared to finasteride, potentially affecting its efficacy in suppressing DHT locally. Microneedling might enhance dutasteride absorption, possibly offering stronger local DHT suppression with fewer systemic effects.

A user had their first dutasteride mesotherapy session in Spain to recover hair on the temple area, with plans for monthly sessions and continued use of topical Minoxidil. If no results are seen in 8 months, they will switch to oral Minoxidil and finasteride.

Dutasteride mesotherapy may stabilize hair loss and improve hair without significantly affecting serum DHT levels, but it can still have systemic effects. Users discuss using topical and oral dutasteride, with some experiencing side effects and considering hair transplants.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The user has been using 0.5 mg dutasteride and 2.5 mg oral minoxidil for a year, recently adding microneedling and topical minoxidil, with some improvement but the crown remains the weakest area. Consistency and realistic expectations are advised, as progress is slow and coverage is challenging with fine hair.

The conversation is about a 21-year-old using finasteride, dermarolling, ketoconazole shampoo, hair growth serums, and exosome therapy to treat early-stage thinning on the crown. They are questioning if these treatments are sufficient to improve hair thickness.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

A user is asking if Dutasteride Mesotherapy and 0.5mg oral Dutasteride are working for their hair regrowth. Another user confirms there is clear and significant progress.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

The conversation discusses the ineffectiveness of tablet forms of dutasteride for hair loss due to poor absorption compared to soft gel capsules. It suggests switching to FDA-approved soft gel capsules for better results, as tablets may not adequately suppress DHT levels.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

Minoxidil, dutasteride, and copper peptides are used in a tattooing method for hair regrowth, with some users noting better results compared to oral treatments. Copper peptides are considered to have minimal impact, but the method may reduce side effects.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

The conversation discusses experiences with Dutasteride Mesotherapy for hair loss. Users share their results and compare it to other treatments like Minoxidil and Finasteride.

The conversation is about making topical finasteride using stemoxydine as a carrier. The user is considering buying Redken Cerafill Hair Re-Densifying Treatment (Stemoxydine) 90ml for this purpose.

A user is planning to use mesotherapy with 0.025% dutasteride for hair maintenance due to intolerance to finasteride. They seek clinics in Northern Germany, Sweden, or nearby countries for dutasteride scalp injections.

A 28-year-old male is experiencing hair loss despite using topical and oral Minoxidil, oral Finasteride, and recently switching to oral Dutasteride. He is considering whether to return to topical Dutasteride or add Dutasteride mesotherapy to better target scalp DHT.

A user's experience with using 5AR inhibitors (Finasteride and Dutasteride) in combination with Minoxidil foam and microneedling, which resulted in substantial improvements to their crown density and hairline, despite high systemic levels of testosterone and dihydrotestosterone.

The user has been using minoxidil for hair loss and is considering trying a compounded topical treatment with 0.1% dutasteride, minoxidil, tretinoin, collagen, and silicon, as recommended by a trichologist. They learned that dutasteride might be more effective than finasteride and are seeking opinions on the use of topical dutasteride.

A user found a solution for Minoxidil-induced dandruff by using a custom NRF 11.121 mixture from a local pharmacy, which includes ingredients like Isopropyl palmitate and Cremophor RH 40. This formulation prevents dryness and allows better penetration when using hair shaders.

The user is seeking a quicker-drying carrier for RU58841 and Minoxidil to improve adherence to their hair loss treatment routine. They want to apply it after a morning shower without affecting their hair's appearance.

The conversation is about trying DS Labs SOD supplements for hair loss, which contain ingredients like Genistein, B-sitosterol, and Biotin. The user is considering adding these supplements to their existing hair care routine.

Finasteride doesn't work, but dutasteride is effective despite side effects. The discussion focuses on the effectiveness of dutasteride mesotherapy for hair loss.

The conversation is about seeking recommendations for clinics in Los Angeles that offer dutasteride mesotherapy for hair loss treatment. The user is asking for experiences and suggestions from the community.

The conclusion of the conversation is that the user has experienced significant hair regrowth using a combination of medications, including dutasteride, RU58841, and minoxidil. They have not experienced any noticeable side effects and are considering a hair transplant in the future.